Fisetin is a senotherapeutic that extends health and lifespan
Matthew J Yousefzadeh, Yi Zhu, Sara J McGowan, Luise Angelini, Heike Fuhrmann-Stroissnigg, Ming Xu, Yuan Yuan Ling, Kendra I Melos, Tamar Pirtskhalava, Christina L Inman, Collin McGuckian, Erin A Wade, Jonathon I Kato, Diego Grassi, Mark Wentworth, Christin E Burd, Edgar A Arriaga, Warren L Ladiges, Tamara Tchkonia, James L Kirkland, Paul D Robbins, Laura J Niedernhofer, Matthew J Yousefzadeh, Yi Zhu, Sara J McGowan, Luise Angelini, Heike Fuhrmann-Stroissnigg, Ming Xu, Yuan Yuan Ling, Kendra I Melos, Tamar Pirtskhalava, Christina L Inman, Collin McGuckian, Erin A Wade, Jonathon I Kato, Diego Grassi, Mark Wentworth, Christin E Burd, Edgar A Arriaga, Warren L Ladiges, Tamara Tchkonia, James L Kirkland, Paul D Robbins, Laura J Niedernhofer
Abstract
Background: Senescence is a tumor suppressor mechanism activated in stressed cells to prevent replication of damaged DNA. Senescent cells have been demonstrated to play a causal role in driving aging and age-related diseases using genetic and pharmacologic approaches. We previously demonstrated that the combination of dasatinib and the flavonoid quercetin is a potent senolytic improving numerous age-related conditions including frailty, osteoporosis and cardiovascular disease. The goal of this study was to identify flavonoids with more potent senolytic activity.
Methods: A panel of flavonoid polyphenols was screened for senolytic activity using senescent murine and human fibroblasts, driven by oxidative and genotoxic stress, respectively. The top senotherapeutic flavonoid was tested in mice modeling a progeroid syndrome carrying a p16INK4a-luciferase reporter and aged wild-type mice to determine the effects of fisetin on senescence markers, age-related histopathology, disease markers, health span and lifespan. Human adipose tissue explants were used to determine if results translated.
Findings: Of the 10 flavonoids tested, fisetin was the most potent senolytic. Acute or intermittent treatment of progeroid and old mice with fisetin reduced senescence markers in multiple tissues, consistent with a hit-and-run senolytic mechanism. Fisetin reduced senescence in a subset of cells in murine and human adipose tissue, demonstrating cell-type specificity. Administration of fisetin to wild-type mice late in life restored tissue homeostasis, reduced age-related pathology, and extended median and maximum lifespan.
Interpretation: The natural product fisetin has senotherapeutic activity in mice and in human tissues. Late life intervention was sufficient to yield a potent health benefit. These characteristics suggest the feasibility to translation to human clinical studies. FUND: NIH grants P01 AG043376 (PDR, LJN), U19 AG056278 (PDR, LJN, WLL), R24 AG047115 (WLL), R37 AG013925 (JLK), R21 AG047984 (JLK), P30 DK050456 (Adipocyte Subcore, JLK), a Glenn Foundation/American Federation for Aging Research (AFAR) BIG Award (JLK), Glenn/AFAR (LJN, CEB), the Ted Nash Long Life and Noaber Foundations (JLK), the Connor Group (JLK), Robert J. and Theresa W. Ryan (JLK), and a Minnesota Partnership Grant (AMAY-UMN#99)-P004610401-1 (JLK, EAA).
Keywords: Aging; Healthspan; Lifespan; Progeria; Senescence; Senolytic.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.
Figures
References
- Tchkonia T., Zhu Y., van Deursen J., Campisi J., Kirkland J.L. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123(3):966–972.
- Lebrasseur N.K., Tchkonia T., Kirkland J.L. Cellular senescence and the biology of aging, disease, and frailty. Nestle Nutr Inst Workshop Ser. 2015;83:11–18.
- Zhu Y., Armstrong J.L., Tchkonia T., Kirkland J.L. Cellular senescence and the senescent secretory phenotype in age-related chronic diseases. Curr Opin Clin Nutr Metab Care. 2014;17(4):324–328.
- Swanson E.C., Manning B., Zhang H., Lawrence J.B. Higher-order unfolding of satellite heterochromatin is a consistent and early event in cell senescence. J Cell Biol. 2013;203(6):929–942.
- Kirkland J.L. Translating the science of aging into therapeuticiInterventions. Cold Spring Harb Perspect Med. 2016;6(3)
- Justice J., Miller J.D., Newman J.C., Hashmi S.K., Halter J., Austad S.N. Frameworks for proof-of-concept clinical trials of interventions that target fundamental aging processes. J Gerontol A Biol Sci Med Sci. 2016;71(11):1415–1423.
- Newman J.C., Milman S., Hashmi S.K., Austad S.N., Kirkland J.L., Halter J.B. Strategies and challenges in clinical trials targeting human aging. J Gerontol A Biol Sci Med Sci. 2016;71(11):1424–1434.
- Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120:513–522.
- Campisi J. d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729–740.
- Farr J.N., Xu M., Weivoda M.M., Monroe D.G., Fraser D.G., Onken J.L. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med. 2017;23(9):1072–1079.
- Jurk D., Wang C., Miwa S., Maddick M., Korolchuk V., Tsolou A. Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. Aging Cell. 2012;11(6):996–1004.
- Jurk D., Wilson C., Passos J.F., Oakley F., Correia-Melo C., Greaves L. Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat Commun. 2014;2:4172.
- Sapieha P., Mallette F.A. Cellular senescence in postmitotic cells: beyond growth arrest. Trends Cell Biol. 2018;(8):595–607.
- Wang E. Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res. 1995;55(11):2284–2292.
- Coppé J.P., Patil C., Rodier F., Sun Y., Muñoz D.P., Goldstein J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853–2868.
- Kuilman T., Peeper D.S. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer. 2009;9:81–94.
- Acosta J.C., Banito A., Wuestefeld T., Georgilis A., Janich P., Morton J.P. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15(8):978–990.
- Coppe J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118.
- Xu M., Tchkonia T., Ding H., Ogrodnik M., Lubbers E.R., Pirtskhalava T. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U S A. 2015;112(46) E6301-E10.
- Xu M., Palmer A.K., Ding H., Weivoda M.M., Pirtskhalava T., White T.A. Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife. 2015
- Nelson G., Wordsworth J., Wang C., Jurk D., Lawless C., Martin-Ruiz C. A senescent cell bystander effect: senescence-induced senescence. Aging Cell. 2012;11(2):345–349.
- Herbig U., Ferreira M., Condel L., Carey D., Sedivy J.M. Cellular senescence in aging primates. Science. 2006;311(5765):1257.
- Tchkonia T., Morbeck D.E., von Zglinicki T., van Deursen J., Lustgarten J., Scrable H. Fat tissue, aging, and cellular senescence. Aging Cell. 2010;9:667–684.
- Baker D.J., Childs B.G., Durik M., Wijers M.E., Sieben C.J., Zhong J. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016;530(7589):184–189.
- Baker D.J., Wijshake T., Tchkonia T., Lebrasseur N.K., Childs B.G., van de Sluis B. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479(7372):232–236.
- Xu MP, T.; Farr, J.N.; Weigand, B.M.; Palmer, A.K.; Weivoda, M.M.; Inman, C.L.; Ogrodnik, M.B.; Hachfeld, C.M.; Fraser, D.G.; Onken, J.L.; Johnson, K.O.; Verzosa, G.C.; Langhi, L.G.; Weigl, M.; Giorgadze, N.; Lebrasseur, N.K.; Miller, J.D.; Jurk, D.; Singh, R.J.; Allison, D.B.; Ejima, K.; Hubbard, G.B.; Ikeno, Y.; Cubro, H.; Garovic, V.D.; Hou, X.; Weroha, S.J.; Robbins, P.D.; Niedernhofer L.J.; Khosla, S.; Tchkonia, T.; Kirkland, J.L. Senolytics Enhance Physical Function in Old Age and Extend Post-Treatment Survival. Nat Med 2018.
- Xu M., Bradley E.W., Weivoda M.M., Hwang S.M., Pirtskhalava T., Decklever T. Transplanted Senescent Cells Induce an Osteoarthritis-like Condition in mice. J Gerontol A Biol Sci Med Sci. 2017;72(6):780–785.
- Kirkland J.L., Tchkonia T., Zhu Y., Niedernhofer L.J., Robbins P.D. The clinical potential of senolytic drugs. J Am Geriatr Soc. 2017;65(10):2297–2301.
- Kirkland J.L., Tchkonia T. Cellular Senescence: a Translational Perspective. EBioMedicine. 2017;21:21–28.
- Zhu Y., Tchkonia T., Pirtskhalava T., Gower A., Ding H., Giorgadze N. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14:644–658.
- Chang J., Wang Y., Shao L., Laberge R.M., Demaria M., Campisi J. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016;22(1):78–83.
- Zhu Y., Doornebal E.J., Pirtskhalava T., Giorgadze N., Wentworth M., Fuhrmann-Stroissnigg H. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY). 2017;9(3):955–963.
- Zhu Y., Tchkonia T., Fuhrmann-Stroissnigg H., Dai H.M., Ling Y.Y., Stout M.B. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016;15(3):428–435.
- Roos C.M., Zhang B., Palmer A.K., Ogrodnik M.B., Pirtskhalava T., Thalji N.M. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell. 2016:Feb:10. [doi: .1111/acel.12458. Epub ahead of print]
- Schafer M.J., White T.A., Iijima K., Haak A.J., Ligresti G., Atkinson E.J. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. 2017;8
- Ogrodnik M, Miwa S, Tchkonia T, Tiniakos D, Wilson CL, Lahat A, et al. Cellular senescence drives age-dependent hepatic steatosis. Nature Commun [In press].
- Childs B.G., Baker D.J., Wijshake T., Conover C.A., Campisi J., van Deursen J.M. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science. 2016;354(6311):472–477.
- Moncsek A., Al-Suraih M.S., Trussoni C.E., O'Hara S.P., Splinter P.L., Zuber C. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2(−/−) ) mice. Hepatology. 2018;67(1):247–259.
- Niedernhofer L.J., Robbins P.D. Senotherapeutics for healthy ageing. Nat Rev Drug Discov. 2018;17(5):377.
- Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428.
- Zhang H., Nimmer P.M., Tahir S.K., Chen J., Fryer R.M., Hahn K.R. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943–951.
- Kirkland J.L., Tchkonia T. Clinical strategies and animal models for developing senolytic agents. Exp Gerontol. 2015;68:19–25.
- Khan N., Syed D.N., Ahmad N., Mukhtar H. Fisetin: a dietary antioxidant for health promotion. Antioxid Redox Signal. 2013;19(2):151–162.
- Adhami V.M., Syed D.N., Khan N., Mukhtar H. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol. 2012;84(10):1277–1281.
- Maher P. How fisetin reduces the impact of age and disease on CNS function. Front Biosci (Schol Ed) 2015;7:58–82.
- Ahmad A., Robinson A.R., Duensing A., van Drunen E., Beverloo H.B., Weisberg D.B. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol. 2008;28(16):5082–5092.
- Burd C.E., Sorrentino J.A., Clark K.S., Darr D.B., Krishnamurthy J., Deal A.M. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell. 2013;152(1–2):340–351.
- Niedernhofer L.J., Odijk H., Budzowska M., van Drunen E., Maas A., Theil A.F. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol. 2004;24(13):5776–5787.
- Fuhrmann-Stroissnigg H., Ling Y.Y., Zhao J., McGowan S.J., Zhu Y., Brooks R.W. Identification of HSP90 inhibitors as a novel class of senolytics. Nat Commun. 2017;8(1):422.
- Robinson A.R., Yousefzadeh M.J., Rozgaja T.A., Wang J., Li X., Tilstra J.S. Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging. Redox Biol. 2018;17:259–273.
- Yousefzadeh M.J., Schafer M.J., Noren Hooten N., Atkinson E.J., Evans M.K., Baker D.J. Circulating levels of monocyte chemoattractant protein-1 as a potential measure of biological age in mice and frailty in humans. Aging Cell. 2018;17(2)
- Ladiges W. Pathology assessment is necessary to validate translational endpoints in preclinical aging studies. Pathobiol Aging Age Relat Dis. 2016;6
- Zhu Y., Tchkonia T., Pirtskhalava T., Gower A.C., Ding H., Giorgadze N. 2015. The Achilles' heel of senescent cells: From transcriptome to senolytic drugs. Aging Cell.
- Giesen C., Wang H.A., Schapiro D., Zivanovic N., Jacobs A., Hattendorf B. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014;11(4):417–422.
- Spitzer M.H., Nolan G.P. Mass Cytometry: Single Cells, many Features. Cell. 2016;165(4):780–791.
- Niedernhofer L.J., Garinis G.A., Raams A., Lalai A.S., Robinson A.R., Appeldoorn E. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature. 2006;444(7122):1038–1043.
- Debacq-Chainiaux F., Erusalimsky J.D., Campisi J., Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-[beta]gal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protocols. 2009;4(12):1798–1806.
- Liu Y., Sanoff H.K., Cho H., Burd C.E., Torrice C., Ibrahim J.G. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009;8(4):439–448.
- Hall B.M., Balan V., Gleiberman A.S., Strom E., Krasnov P., Virtuoso L.P. Aging of mice is associated with p16(Ink4a)- and beta-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. Aging (Albany NY). 2016;8(7):1294–1315.
- Prattichizzo F., Bonafe M., Olivieri F., Franceschi C. Senescence associated macrophages and "macroph-aging": are they pieces of the same puzzle? Aging (Albany NY) 2016;8(12):3159–3160.
- Khan W.A., Chisholm R., Tadayyon S., Subasinghe A., Norton P., Samarabandu J. Relating centromeric topography in fixed human chromosomes to alpha-satellite DNA and CENP-B distribution. Cytogenet Genome Res. 2013;139(4):234–242.
- Hall B.M., Balan V., Gleiberman A.S., Strom E., Krasnov P., Virtuoso L.P. p16(Ink4a) and senescence-associated beta-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Aging (Albany NY). 2017;9(8):1867–1884.
- Ladiges W., Snyder J.M., Wilkinson E., Imai D.M., Snider T., Ge X. A new preclinical paradigm for testing anti-aging therapeutics. J Gerontol A Biol Sci Med Sci. 2017;72(6):760–762.
- Kirkwood T.B. Understanding ageing from an evolutionary perspective. J Intern Med. 2008;263(2):117–127.
- Passos J.F., von Zglinicki T., Kirkwood T.B. Mitochondria and ageing: winning and losing in the numbers game. BioEssays. 2007;29(9):908–917.
- Vijg J., Campisi J. Puzzles, promises and a cure for ageing. Nature. 2008;454(7208):1065–1071.
- Campisi J., Vijg J. Does damage to DNA and other macromolecules play a role in aging? If so, how? J Gerontol A Biol Sci Med Sci. 2009;64((2):175–178.
- Hoeijmakers J.H. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475–1485.
- Franceschi C., Bonafe M., Valensin S., Olivieri F., De Luca M., Ottaviani E. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–254.
- Krishnamurthy J., Torrice C., Ramsey M.R., Kovalev G.I., Al-Regaiey K., Su L. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004;114(9):1299–1307.
- Lavasani M., Robinson A.R., Lu A., Song M., Feduska J.M., Ahani B. Muscle-derived stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria model. Nat Commun. 2012;3:608.
- Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656–660.
- Iannello A., Thompson T.W., Ardolino M., Lowe S.W., Raulet D.H. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med. 2013;210(10):2057–2069.
- Touil Y.S., Auzeil N., Boulinguez F., Saighi H., Regazzetti A., Scherman D. Fisetin disposition and metabolism in mice: Identification of geraldol as an active metabolite. Biochem Pharmacol. 2011;82(11):1731–1739.
- Gurau F., Baldoni S., Prattichizzo F., Espinosa E., Amenta F., Procopio A.D. Anti-senescence compounds: a potential nutraceutical approach to healthy aging. Ageing Res Rev. 2018;46:14–31.
- Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191–196.
- Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature. 2004;430(7000):686–689.
- Kimira M., Arai Y., Shimoi K., Watanabe S. Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol. 1998;8(3):168–175.
- Arai Y., Watanabe S., Kimira M., Shimoi K., Mochizuki R., Kinae N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr. 2000;130(9):2243–2250.
- Syed D.N., Adhami V.M., Khan M.I., Mukhtar H. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem. 2013;13(7):995–1001.
- Salerno S., Da Settimo F., Taliani S., Simorini F., La Motta C., Fornaciari G. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. Curr Med Chem. 2010;17(35):4270–4290.
- Gupta S.C., Tyagi A.K., Deshmukh-Taskar P., Hinojosa M., Prasad S., Aggarwal B.B. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch Biochem Biophys. 2014;559:91–99.
- Ishige K., Schubert D., Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med. 2001;30(4):433–446.
- Prasath G.S., Subramanian S.P. Antihyperlipidemic effect of fisetin, a bioflavonoid of strawberries, studied in streptozotocin-induced diabetic rats. J Biochem Mol Toxicol. 2014;28(10):442–449.
- Zheng L.T., Ock J., Kwon B.M., Suk K. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. Int Immunopharmacol. 2008;8(3):484–494.
- Prasath G.S., Subramanian S.P. Fisetin, a tetra hydroxy flavone recuperates antioxidant status and protects hepatocellular ultrastructure from hyperglycemia mediated oxidative stress in streptozotocin induced experimental diabetes in rats. Food Chem Toxicol. 2013;59:249–255.
- Sagara Y., Vanhnasy J., Maher P. Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal-regulated kinase activation. J Neurochem. 2004;90(5):1144–1155.
Source: PubMed